BUSINESS

FDA Advisors Back Full Approval of Eisai’s Alzheimer’s Med

June 12, 2023

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

An advisory panel of the US FDA on June 9 unanimously recommended full approval of Eisai’s Alzheimer’s disease therapy Leqembi (lecanemab). The agency is set to deliver a decision by July 6, with a likely clearance expected to pave the…

To read the full story

Leqembi Likely to Face 15% Price Cut Under Special CEA Rule
July 10, 2025
Eisai CEO Anticipates Leqembi Approval in Europe and China by March
December 18, 2023
Leqembi to Cost 2.98 Million Yen per Year, Re-Pricing Might Be Triggered on Patient Upswing
December 14, 2023
Leqembi to Debut on Dec. 20; Eisai Sees SC Version and Blood Biomarker as Drivers for Wider Use
December 14, 2023
Leqembi OK’ed for Listing on Dec. 20; Peak Sales Put at 98.6 Billion Yen
December 13, 2023
Chuikyo Agrees to Adopt Normal Rules to Price, Re-Price Leqembi
November 16, 2023
Industry Prods Careful Debate on Creating Separate Rules for Leqembi Re-Pricing
November 9, 2023
Medical, Long-Term Care Data Linkage Holds Key to CEA: Leqembi Debate
October 30, 2023
Leqembi’s Initial Pricing Won’t Factor in Benefits in Long-Term Care
October 19, 2023
Post-Launch Re-Pricing Likely the Focus of Chuikyo Leqembi Discussions
October 5, 2023
As Chuikyo Begins Pricing Debate of Leqembi, Panelists Urge Safety, Fair Access
September 28, 2023
Leqembi Subject to Cost Control Rule for Potential Big Sellers, MHLW Still Set to Meet Listing Deadline
September 26, 2023
Japan Approves Eisai/Biogen’s Alzheimer’s Drug Leqembi
September 25, 2023
Eisai’s Alzheimer’s Drug Clears Advisory Panel, Now in Line for Japan Approval
August 22, 2023
Full US Nod in Hand, Eisai CEO Keeps 1 Trillion Yen Sales Target for FY2030
July 10, 2023
FDA Awards Full Approval to Eisai’s Alzheimer’s Drug
July 7, 2023

BUSINESS

Pharma Hails End to “Spillover” Rule, Vows to Keep Fighting Off-Year Cuts
December 25, 2025
Drug Wholesalers Slam “No-Discussion” Decision on FY2027 Off-Year Price Revision
December 25, 2025
JCR Earns Japan Rights to DMD Drug from Italfarmaco
December 25, 2025
Fujifilm Completes Major Biologics CDMO Plant in Toyama, Eyes 2027 Start-Up
December 25, 2025
Alfresa’s Cell Resources Inks Partnership with Korea’s ENCell
December 25, 2025

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo Backs Draft FY2026 Pricing Reform Outline, Rejects Key Industry Requests

By Takashi Ebisawa

The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…

COLUMN

AI: Your New HR BFF (Not Your Replacement!)

By Philip Carrigan

Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…

COMMENTARY

Radioligand Therapy Faces Capacity Bottleneck in Japan, System Build-Out Needed to Deliver on Promise

By Koji Shimomura

Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…